NEET-PG 2013 Practice Questions

Q: Which of the following is a second-generation beta blocker?

Atenolol. ***Atenolol*** - **Atenolol** is a **second-generation beta blocker** characterized by its **cardioselectivity**, meaning it primarily blocks beta-1 receptors in the heart. - This selectively reduces heart rate and contractility with fewer respiratory side effects compared to non-selective agents. *Propranolol* - **Propranolol** is a **first-generation non-selective beta blocker**, meaning it blocks both beta-1 and beta-2 adrenergic receptors. - Its non-selective action can cause significant bronchoconstriction, making it less suitable for patients with respiratory conditions. *Timolol* - **Timolol** is also a **first-generation non-selective beta blocker** commonly used in ophthalmic preparations for glaucoma. - It blocks both beta-1 and beta-2 receptors and does not possess the cardioselectivity of second-generation agents. *Nadolol* - **Nadolol** is another **first-generation non-selective beta blocker** with a long duration of action due to its extensive plasma half-life. - Like other first-generation agents, it lacks cardioselectivity and blocks both beta-1 and beta-2 receptors.

Q: Which of the following is not a recognized use of alpha-2-agonists?

Benign Hyperplasia of prostate. ***Correct Answer: Benign Hyperplasia of prostate*** - Alpha-2-agonists are **NOT** used to treat **benign prostatic hyperplasia (BPH)**; this condition is typically managed with **alpha-1-blockers** (e.g., tamsulosin, alfuzosin) or 5-alpha-reductase inhibitors. - Alpha-1-blockers relax the smooth muscle in the prostate and bladder neck, improving urine flow, which involves a different receptor mechanism than alpha-2-agonists. - Alpha-2-agonists would not provide therapeutic benefit for BPH. *Incorrect: Glaucoma* - Alpha-2-agonists (e.g., **brimonidine**, **apraclonidine**) **are** used to treat **glaucoma** by reducing aqueous humor production and increasing uveoscleral outflow. - This action helps to **lower intraocular pressure**, a primary goal in glaucoma management. *Incorrect: Hypertension* - Central-acting alpha-2-agonists (e.g., **clonidine**, **methyldopa**) **are** used as **antihypertensive agents**. - They reduce sympathetic outflow from the central nervous system, leading to decreased heart rate, vasodilation, and consequently, **lower blood pressure**. *Incorrect: Sedation* - Alpha-2-agonists like **dexmedetomidine** and **clonidine** **are** commonly used for **sedation** in critically ill patients, especially in intensive care units. - They produce sedation, analgesia, and anxiolysis without causing significant respiratory depression, making them valuable in certain clinical settings.

Q: Which urinary bladder spasmolytic has local anesthetic properties?

Oxybutynin. ***Oxybutynin*** - Possesses both **anticholinergic properties** (bladder smooth muscle relaxation) and **direct local anesthetic properties**, which contribute to its spasmolytic effect on the detrusor muscle. - The **local anesthetic action** directly reduces bladder detrusor muscle contractions, explaining its efficacy in treating urge incontinence and overactive bladder. - This dual mechanism makes it unique among bladder spasmolytics. *Tamsulosin* - Is an **alpha-1 adrenergic receptor blocker** used for benign prostatic hyperplasia (BPH) by relaxing smooth muscle in the prostate and bladder neck. - Does **not have local anesthetic properties** and is not a bladder detrusor spasmolytic. *Terazosin* - Also an **alpha-1 adrenergic receptor blocker**, similar to tamsulosin, used for BPH and hypertension. - Acts via **vascular and prostatic smooth muscle relaxation**, without local anesthetic or bladder spasmolytic effects. *Yohimbine* - Is an **alpha-2 adrenergic receptor antagonist** known for increasing sympathetic outflow. - Does **not have bladder spasmolytic effects** or local anesthetic properties.

Q: Which dopamine receptor is known for its inhibitory action in the central nervous system?

Dopamine Receptor D2. ***Dopamine Receptor D2*** - The **D2 receptor** is a member of the D2-like family (D2, D3, D4), which are **G-protein coupled receptors** that inhibit adenylyl cyclase activity. - Its activation typically leads to a **decrease in neuronal excitability** and neurotransmitter release, providing an inhibitory effect in the CNS. *Dopamine Receptor D5* - The **D5 receptor** belongs to the D1-like family (D1, D5), which are **G-protein coupled receptors** that stimulate adenylyl cyclase activity. - Activation of D5 receptors typically leads to **excitatory effects** rather than inhibitory ones in the CNS. *No inhibitory dopamine receptor present* - This statement is incorrect as specific dopamine receptor subtypes, particularly the **D2-like family**, are well-established to exert inhibitory actions in the CNS. - These inhibitory effects are crucial for various physiological processes, including motor control and reward pathways. *Dopamine Receptor D1* - The **D1 receptor** is part of the D1-like family (D1, D5) and is known for its **excitatory effects** in the CNS. - Activation of D1 receptors leads to an **increase in intracellular cAMP** and generally enhances neuronal activity.

Q: Which of the following is classified as an antispasmodic agent?

Dicyclomine. ***Dicyclomine*** - **Dicyclomine** is an **anticholinergic** medication that works by blocking muscarinic receptors, thereby reducing smooth muscle spasm in the gastrointestinal tract. - It is commonly used to treat symptoms of **irritable bowel syndrome (IBS)**, such as abdominal pain and cramping. *Physostigmine* - **Physostigmine** is a **cholinesterase inhibitor** that increases the concentration of acetylcholine at the synaptic cleft. - It is used to treat **anticholinergic poisoning** by reversing the effects of anticholinergic drugs, rather than acting as an antispasmodic itself. *Tropicamide* - **Tropicamide** is an **anticholinergic** agent primarily used as a **mydriatic** (pupil dilator) and **cycloplegic** (paralyzes the ciliary muscle) for ophthalmic examinations. - Its action is localized to the eye and it does not have significant systemic antispasmodic effects. *None of the options* - This option is incorrect because one of the listed medications is indeed classified as an antispasmodic agent. - When "None of the options" appears as a choice, it should only be selected if all other options are clearly incorrect.

Q: Which beta-1 antagonist is used in congestive cardiac failure?

Metoprolol. ***Metoprolol*** - **Metoprolol succinate** (extended-release formulation) is a selective **beta-1 antagonist** proven to reduce mortality and hospitalizations in **chronic heart failure with reduced ejection fraction (HFrEF)**. - It works by **reducing heart rate, myocardial oxygen demand**, and preventing adverse cardiac remodeling through inhibition of chronic sympathetic activation. - Along with **bisoprolol and carvedilol**, it is one of the **three beta-blockers with proven mortality benefit** in heart failure trials. *Atenolol* - While atenolol is a selective beta-1 antagonist, it **lacks evidence for mortality benefit** in heart failure. - It has **high hydrophilicity** and renal elimination, leading to less favorable pharmacokinetics compared to metoprolol. - More commonly used for **hypertension and angina** rather than heart failure management. *Esmolol* - **Esmolol** is an ultra-short-acting selective beta-1 antagonist used for **acute control of heart rate** in perioperative and critical care settings. - Its **very short half-life (9 minutes)** makes it unsuitable for chronic management of heart failure. - Administered only **intravenously** and requires continuous infusion. *Bisoprolol* - While **bisoprolol is also approved** for heart failure and has proven mortality benefit (CIBIS-II trial), this question likely expects **metoprolol** as the answer given the historical context. - Both bisoprolol and metoprolol are acceptable answers, but **metoprolol** has been more widely studied and is more commonly cited in Indian medical exams. - Bisoprolol has **greater beta-1 selectivity** than metoprolol but similar clinical outcomes in heart failure.

Q: Muscarinic cholinergic receptors are seen at all sites, except?

Neuromuscular junction. ***Neuromuscular junction*** - The **neuromuscular junction** primarily contains **nicotinic cholinergic receptors**, not muscarinic receptors. - Activation of these nicotinic receptors by acetylcholine causes muscle contraction. *Stomach* - The stomach contains **muscarinic M3 receptors** which mediate gastric acid secretion and smooth muscle contraction. - Activation by acetylcholine via the vagus nerve promotes digestion. *CNS* - The **central nervous system** has various subtypes of **muscarinic receptors (M1-M5)** distributed throughout, playing roles in learning, memory, and motor control. - These receptors modulate neuronal excitability and neurotransmitter release. *Glands* - Most exocrine glands (e.g., salivary, lacrimal, sweat glands) are richly supplied with **muscarinic receptors**, primarily **M3**. - Activation leads to increased glandular secretion.

Q: Which antiglaucomatous drug is known to cause spasm of accommodation?

Pilocarpine. ***Pilocarpine*** - **Pilocarpine** is a **direct-acting muscarinic agonist** that contracts the **ciliary muscle**. - Contraction of the ciliary muscle leads to **accommodation spasm** and a forward movement of the **iris-lens diaphragm**, which also helps to open the **trabecular meshwork**, facilitating aqueous outflow. *Timolol* - **Timolol** is a **beta-blocker** that reduces aqueous humor production by blocking beta-adrenergic receptors on the ciliary epithelium. - It does not directly affect the **ciliary muscle** or cause accommodation spasm. *Dorazolamide* - **Dorzolamide** is a **carbonic anhydrase inhibitor** that reduces aqueous humor production. - Its mechanism of action does not involve the ciliary body's mechanical action and therefore does not cause **accommodation spasm**. *Latanoprost* - **Latanoprost** is a **prostaglandin analog** that increases uveoscleral outflow of aqueous humor. - It does not directly affect the ciliary muscle's contraction or cause **accommodation spasm**.

Q: Besides its properties of decreasing intraocular pressure, timolol is preferred in the treatment of glaucoma because it

Produces no miosis. ***Produces no miosis*** - Timolol, a **non-selective beta-blocker**, decreases intraocular pressure without affecting pupillary size. - This is a **key advantage** in glaucoma treatment as miosis (pupil constriction) can worsen vision, especially in patients with cataracts. - Unlike **miotics** (e.g., pilocarpine), timolol does not cause pupillary constriction, making it better tolerated. *Possesses membrane stabilizing activity* - While some beta-blockers possess **membrane-stabilizing activity** (local anesthetic effect), this property is not a primary reason for timolol's preference in glaucoma. - This action is more relevant in antiarrhythmic uses of beta-blockers due to its effect on cardiac action potentials. *Increases outflow of aqueous humor* - Timolol primarily reduces intraocular pressure by **decreasing the production of aqueous humor**, not by increasing its outflow. - Drugs like **pilocarpine** (a cholinergic agonist) or **prostaglandin analogs** increase outflow. *Is a selective beta-adrenoceptor blocker* - Timolol is a **non-selective beta-blocker**, meaning it blocks both beta-1 and beta-2 adrenergic receptors. - Its non-selectivity is associated with systemic side effects (e.g., bronchospasm, bradycardia), and selective beta-blockers like **betaxolol** exist but are not the primary reason for timolol's preference in glaucoma.

Q: Which of the following develop first during dependence of a substance ?

Psychological dependence. ***Psychological dependence*** - **Psychological dependence** often develops first, characterized by an emotional need for the substance to experience pleasure or avoid discomfort. - This involves a strong **craving** and compulsive drug-seeking behavior despite negative consequences, driven by the substance's effect on brain reward pathways. *Tolerance* - **Tolerance** means that increasing doses of the substance are required to achieve the same effect previously achieved with lower doses. - While it often develops early in substance use, the initial "need" to use the substance is often psychological before physiological adaptations occur. *Physical dependence* - **Physical dependence** describes the body's physiological adaptation to the substance, leading to withdrawal symptoms if use is stopped or reduced. - It typically develops after consistent, prolonged use and is usually preceded by psychological dependence and often tolerance. *Withdrawal symptoms* - **Withdrawal symptoms** are the physiological and psychological signs that occur when a dependent person stops or drastically reduces their substance intake. - These are a direct manifestation of physical dependence and thus develop once physical dependence has been established.

Question 1

Which of the following is a second-generation beta blocker?

Accepted Answer

Atenolol

Answer

Timolol

Answer

Nadolol

Answer

Propranolol

Question 2

Which of the following is not a recognized use of alpha-2-agonists?

Accepted Answer

Benign Hyperplasia of prostate

Answer

Glaucoma

Answer

Hypertension

Answer

Sedation

Question 3

Which urinary bladder spasmolytic has local anesthetic properties?

Accepted Answer

Oxybutynin

Answer

Tamsulosin

Answer

Terazosin

Answer

Yohimbine

Question 4

Which dopamine receptor is known for its inhibitory action in the central nervous system?

Accepted Answer

Dopamine Receptor D2

Answer

Dopamine Receptor D5

Answer

No inhibitory dopamine receptor present

Answer

Dopamine Receptor D1

Question 5

Which of the following is classified as an antispasmodic agent?

Accepted Answer

Dicyclomine

Answer

Physostigmine

Answer

Tropicamide

Answer

None of the options

Question 6

Which beta-1 antagonist is used in congestive cardiac failure?

Accepted Answer

Metoprolol

Answer

Atenolol

Answer

Esmolol

Answer

Bisoprolol

Question 7

Muscarinic cholinergic receptors are seen at all sites, except?

Accepted Answer

Neuromuscular junction

Answer

Stomach

Answer

CNS

Answer

Glands

Question 8

Which antiglaucomatous drug is known to cause spasm of accommodation?

Accepted Answer

Pilocarpine

Answer

Timolol

Answer

Dorzolamide

Answer

Latanoprost

Question 9

Besides its properties of decreasing intraocular pressure, timolol is preferred in the treatment of glaucoma because it

Accepted Answer

Produces no miosis

Answer

Is a selective beta-adrenoceptor blocker

Answer

Increases outflow of aqueous humor

Answer

Possesses membrane stabilizing activity

Question 10

Which of the following develop first during dependence of a substance ?

Accepted Answer

Psychological dependence

Answer

Tolerance

Answer

Physical dependence

Answer

Withdrawal symptoms

NEET-PG 2013

Pharmacology

Psychiatry